A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

Official record

Identifier

NCT07691762

Recruiting locations

country

China

Interventions studied

SHR-8068 + Adebrelimab + BevacizumabSHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab PlaceboSHR-8068 Placebo + Adebrelimab + Bevacizumab

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target enrolment

690 participants

Study type

INTERVENTIONAL

Phase

Phase 3

Status

Not yet recruiting

First posted

Jul 9, 2026

Last updated on the registry

Sep 28, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Age 18-75 years old, male or female;
2. Diagnosis confirmed HCC by pathologically or clinically;
3. At least one measurable lesion;
4. Child-Pugh liver function grade A;
5. ECOG-PS score: 0 or 1;
6. Eligible for TACE treatment as assessed by the investigator;
7. Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
8. Consent to contraception.

Exclusion Criteria:

1. Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
2. Participants with any active, known or suspected autoimmune disorder;
3. Participants with hypertension which cannot be well controlled by antihypertensives;
4. Uncontrolled cardiac diseases or symptoms;
5. Participants with hepatic encephalopathy;
6. Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
7. History of gastrointestinal perforation and/or fistula;
8. Participants with other potential factors that may affect the study results.

Indexed under

Liver Cancer